Back to Search Start Over

Molecular mechanisms underlying Tao-Hong-Si-Wu decoction treating hyperpigmentation based on network pharmacology, Mendelian randomization analysis, and experimental verification.

Authors :
Chen J
Ye W
Source :
Pharmaceutical biology [Pharm Biol] 2024 Dec; Vol. 62 (1), pp. 296-313. Date of Electronic Publication: 2024 Mar 31.
Publication Year :
2024

Abstract

Context: Hyperpigmentation, a common skin condition marked by excessive melanin production, currently has limited effective treatment options.<br />Objective: This study explores the effects of Tao-Hong-Si-Wu decoction (THSWD) on hyperpigmentation and to elucidate the underlying mechanisms.<br />Materials and Methods: We employed network pharmacology, Mendelian randomization, and molecular docking to identify THSWD's hub targets and mechanisms against hyperpigmentation. The Cell Counting Kit-8 (CCK-8) assay determined suitable THSWD treatment concentrations for PIG1 cells. These cells were exposed to graded concentrations of THSWD-containing serum (2.5%, 5%, 10%, 15%, 20%, 30%, 40%, and 50%) and treated with α-MSH (100 nM) to induce an in vitro hyperpigmentation model. Assessments included melanin content, tyrosinase activity, and Western blotting.<br />Results: ALB, IL6, and MAPK3 emerged as primary targets, while quercetin, apigenin, and luteolin were the core active ingredients. The CCK-8 assay indicated that concentrations between 2.5% and 20% were suitable for PIG1 cells, with a 50% cytotoxicity concentration (CC <subscript>50</subscript> ) of 32.14%. THSWD treatment significantly reduced melanin content and tyrosinase activity in α-MSH-induced PIG1 cells, along with downregulating MC1R and MITF expression. THSWD increased ALB and p-MAPK3/MAPK3 levels and decreased IL6 expression in the model cells.<br />Discussion and Conclusion: THSWD mitigates hyperpigmentation by targeting ALB, IL6, and MAPK3. This study paves the way for clinical applications of THSWD as a novel treatment for hyperpigmentation and offers new targeted therapeutic strategies.

Details

Language :
English
ISSN :
1744-5116
Volume :
62
Issue :
1
Database :
MEDLINE
Journal :
Pharmaceutical biology
Publication Type :
Academic Journal
Accession number :
38555860
Full Text :
https://doi.org/10.1080/13880209.2024.2330609